The CDMO’s latest investment will boost capacity at its Charles City, IA facility by 40%, underscoring Cambrex’s focus on ...

Though riddled with inconsistencies, the report indicates hundreds of thousands of arrests are still being made for marijuana ...

Cambrex will invest $120M to expand U.S. drug manufacturing, boosting API capacity at its Iowa site and adding jobs amid ...

In a press release, Cambrex CEO Thomas Loewald calls the Charles City site the largest independent API manufacturing facility ...

The Charles City facility, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, ...

Success with a smart VF is less about the screens and more about how people interact with the data and each other.

We wanted to know where a widely used prescription drug that treats high cholesterol was manufactured and whether the factory ...

Lonza Group said its third-quarter performance was strong, with a return to growth at its capsules-and-health ingredients unit, and that it is on track to achieve full-year guidance for its core ...

Swiss contract drug manufacturer Lonza confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business.

It's the latest in a string of announcements by pharmaceutical manufacturers to build or expand operations in Virginia.

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments.